Oxybuprocaine
 | |
|---|---|
| Systematic (IUPAC) name | |
| 2-diethylaminoethyl 4-amino-3-butoxy-benzoate | |
| Identifiers | |
| CAS number | 99-43-4 |
| ATC code | D04AB03 S01HA02 |
| PubChem | CID 4633 |
| DrugBank | APRD00817 |
| ChemSpider | 4472 |
| UNII | AXQ0JYM303 |
| KEGG | D08319 |
| ChEMBL | CHEMBL1200 |
| Chemical data | |
| Formula | C17H29ClN2O3 |
| Mol. mass | 344.877 g/mol |
| SMILES | eMolecules & PubChem |
| Therapeutic considerations | |
| Pregnancy cat. | D(AU) |
| Legal status | ? |
 (what is this?) (verify) | |
Oxybuprocaine (INN), also known as benoxinate or BNX, is the name of a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine is sold by Novartis under the brand names Novesine or Novesin.
Safety for use in pregnancy and lactation has not been established.
Surgical use
Adverse effects
Oxybuprocaine like any other topical anesthetic used in the eye (like for example tetracaine, proxymetacaine and proparacaine) can cause irreversible corneal damage and even complete destruction of the cornea when used excessively (excessive use means several times a day during several days or even weeks).
See also
Retrieved from : http://en.wikipedia.org/wiki/Oxybuprocaine
